Crossmark

The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors

Crossref DOI link: https://doi.org/10.1186/s40425-019-0768-9

Published Online: 2019-10-26

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Davis, Andrew A.

Patel, Vaibhav G. https://orcid.org/0000-0003-2004-7298
License Information

Text and Data Mining valid from 2019-10-26
More Information

Article History

Received: 28 May 2019

Accepted: 5 October 2019

First Online: 26 October 2019

Ethics approval and consent to participate

: Not applicable

: Not applicable

: The authors declare that they have no competing interests relevant to this work.

Document is current

Any future updates will be listed below